Robert Connor

Robert Connor is a highly experienced scientist with a focus on biological chemistry and extensive expertise in cancer research and drug development. Currently serving as a Senior Principal Scientist I at Halozyme, Inc. since 2016, Connor has contributed significantly to projects involving high-speed subcutaneous dosing and the characterization of molecular entities for insulin coformulation. Prior roles at IGNYTA, Inc. and Halozyme Therapeutics, Inc. involved generating mechanism of action data for cancer therapies and leading collaborations to develop novel tumor models. With earlier experience at Schering Plough Biopharma Corp, Connor played a key role in advancing gene therapy programs for bladder cancer. Connor holds a Ph.D. from the UCLA School of Medicine and a BA in Biochemistry and Molecular Biology from UC Santa Barbara.